



Yale School of Medicine Seminars in Human and Translational Immunology

"Tolerogenic and anti-inflammatory uses of biodegradable PLG nanoparticles for treatment of auto(immune) diseases – mechanisms and clinical prospects"

Stephen D. Miller, Ph.D.

Judy Gugenheim Research Professor Director-Interdepartmental Immunobiology Center Department of Microbiology-Immunology Northwestern University Medical School

Host: Dr. Jordan S. Pober February 12, 2013 @ 4 p.m. - The Anlyan Center - TAC N203

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NEEDS ASSESSMENT

The HTI program at Yale University School of Medicine is a FOCIS (Federation of Clinical immunology Societies) Center of Excellence. The mission of the FCEs is to create an integrated community among immunologists in different departments and sections at individual medical schools, allowing for exchange of information and development of interdisciplinary collaborations

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Describe the role of epitope spreading in the pathogenesis of autoimmune diseases
- Understand the principles underlying immunosuppression and specific immune tolerance for treatment of immune-mediated diseases
- Understand the mechanisms by which tolerance is induced by uptake of apoptotic cells and surrogate biodegradable PLG nanoparticles

DESIGNATION STATEMENT

The Yale School of Medicine designates this educational activity for 1 *AMA PRA Category 1 Credit(s)*TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.